Jeffrey Jewell - Wesana Health VP Affairs
| WSNAF Stock | USD 0 0 28.33% |
Insider
Jeffrey Jewell is VP Affairs of Wesana Health Holdings
| Phone | 773 236 7972 |
| Web | https://www.wesanahealth.com |
Jeffrey Jewell Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Jewell against Wesana Health pink sheet is an integral part of due diligence when investing in Wesana Health. Jeffrey Jewell insider activity provides valuable insight into whether Wesana Health is net buyers or sellers over its current business cycle. Note, Wesana Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Wesana Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Jewell over a month ago Disposition of 12083 shares by Jeffrey Jewell of DT Midstream subject to Rule 16b-3 | ||
Jeffrey Jewell over three months ago Acquisition by Jeffrey Jewell of 200 shares of DT Midstream at 74.22 subject to Rule 16b-3 | ||
Jeffrey Jewell over a year ago Purchase by Jeffrey Jewell of 298 shares of DT Midstream | ||
Jeffrey Jewell over a year ago Purchase by Jeffrey Jewell of 358 shares of DT Midstream |
Wesana Health Management Efficiency
The company has return on total asset (ROA) of (0.4236) % which means that it has lost $0.4236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7162) %, meaning that it generated substantial loss on money invested by shareholders. Wesana Health's management efficiency ratios could be used to measure how well Wesana Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Joseph Ferra | Elevation Oncology | 49 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Jonathan Pachter | Verastem | 66 | |
| Erin Cox | Verastem | N/A | |
| BPHARM RPh | Verastem | 63 | |
| David Dornan | Elevation Oncology | 46 | |
| Piyush Gupta | Verastem | N/A | |
| Daniel Calkins | Verastem | 36 | |
| Valerie MD | Elevation Oncology | 46 | |
| Stephen JD | Geron | 74 | |
| Robert Weinberg | Verastem | N/A | |
| Sean Flynn | Verastem | 50 | |
| Michelle MD | Verastem | 48 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Mba MBA | Verastem | 70 | |
| Wolfgang MD | Rigel Pharmaceuticals | 58 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Christian Mueller | Immutep Ltd ADR | N/A | |
| Shengfei Fang | Immutep Ltd ADR | N/A | |
Management Performance
| Return On Equity | -1.72 | |||
| Return On Asset | -0.42 |
Wesana Health Holdings Leadership Team
Elected by the shareholders, the Wesana Health's board of directors comprises two types of representatives: Wesana Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Wesana. The board's role is to monitor Wesana Health's management team and ensure that shareholders' interests are well served. Wesana Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Wesana Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Carcillo, CEO CoFounder | ||
| Jeffrey Jewell, VP Affairs | ||
| Zed Wang, CFO Sec | ||
| Mark Wingertzahn, Chief Officer | ||
| Chad Bronstein, CoFounder | ||
| Keenan Gentry, VP Devel | ||
| Izzy Forman, VP Communications |
Wesana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Wesana Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.72 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (49.56) % | |||
| Current Valuation | (851.39 K) | |||
| Shares Outstanding | 20.49 M | |||
| Shares Owned By Insiders | 4.64 % | |||
| Shares Owned By Institutions | 13.77 % | |||
| Price To Book | 0.21 X | |||
| Price To Sales | 2.53 X | |||
| Revenue | 267.2 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Wesana Pink Sheet
Wesana Health financial ratios help investors to determine whether Wesana Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Wesana with respect to the benefits of owning Wesana Health security.